Precision medicine: Sustained response to erdafitinib in FGFR2‐mutant, multiply recurrent ameloblastoma
Abstract Background Ameloblastoma imposes significant morbidity and high‐recurrence rates following surgery and radiation therapy. Although 89% of cases harbor oncogenic mutations, the role of targeted therapy is undefined. Case We describe a case of a 40‐year‐old male with multiply recurrent, local...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-10-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1656 |